Breaking News Instant updates and real-time market news.

DVAX

Dynavax

$10.82

0.05 (0.46%)

, MRK

Merck

$62.77

0.11 (0.18%)

17:24
10/09/16
10/09
17:24
10/09/16
17:24

Dynavax reports Phase 1/2 data on SD-101

Dynavax Technologies (DVAX) announced the first presentation of findings from an ongoing Phase 1/2 study evaluating SD-101 in combination with Keytruda, Merck's (MRK) anti-PD-1 treatment. Early results evaluating five patients with metastatic melanoma for efficacy and 16 patients for safety were reported. In patients naive to anti-PD-1 treatment objective responses were observed in three out of four, including one complete response and two partial responses. One patient with progressive disease while receiving anti-PD-1 therapy was observed to have stable disease. SD-101 in combination with pembrolizumab was well-tolerated. No dose-limiting toxicities of the combination were observed in any dose cohort, and a maximum tolerated dose was not identified. No immune-related adverse events were reported, and the most common treatment-emergent adverse events were grade 1-2 flu-like symptoms, including fever, chills and myalgia consistent with the engagement of TLR9 and production of interferon alpha. The study also included biomarker assessments suggesting that treatment with SD-101 and pembrolizumab resulted in elevation of gene signatures consistent with an increase in immune cell types and multiple immune functions.

DVAX

Dynavax

$10.82

0.05 (0.46%)

MRK

Merck

$62.77

0.11 (0.18%)

  • 25

    Oct

  • 06

    Nov

  • 16

    Nov

  • 15

    Dec

DVAX Dynavax
$10.82

0.05 (0.46%)

04/27/16
COWN
04/27/16
NO CHANGE
Target $60
COWN
Outperform
Dynavax PDUFA extension will not impact approval chances, says Cowen
Cowen analyst Phil Nadeau does not beleive Dynavax's Heplisav PDUFA extension by 3 months will impact chances of approval. The analyst suspects that the PDUFA change has more to do with FDA managing its workload than any reflection on the substance of the BLA, since both the FDA and Dynavax had agreed upon the original format of the BLA resubmission. Nadeau continues to rate Dynavax an Outperform and top small cap pick with a $60 price target on shares.
04/27/16
RBCM
04/27/16
DOWNGRADE
RBCM
Sector Perform
Dynavax downgraded to Sector Perform from Outperform at RBC Capital
04/28/16
RBCM
04/28/16
DOWNGRADE
RBCM
Sector Perform
Dynavax downgraded on drug safety concerns at RBC Capital
As noted earlier, RBC Capital downgraded Dynavax to Sector Perform from Outperform, The firm cited concerns about the safety of the company's Heplisav-B drug as the reason for its downgrade. RBC says that the FDA's decision to request individual trial data instead of the integrated dataset shows that the agency's scrutiny of the drug's safety has increased. Target to $17 from $48.
09/06/16
WBLR
09/06/16
NO CHANGE
WBLR
Outperform
FDA panel cancelation positive for Dynavax, says William Blair
William Blair analyst Y. Katherine Xu views the FDA's decision to canceled the November 16 Vaccines and Related Biological Products Advisory Committee meeting for Heplisav as a net positive for Dynavax. The agency's decision to move straight to the PDUFA date suggests that the Heplisav package is "sufficiently strong and adequate to warrant approval in the absence of a panel," Xu tells investors in a research note. She keeps an Outperform rating on Dynavax. The stock is up 19% to $13.00 in pre-market trading.
MRK Merck
$62.77

0.11 (0.18%)

09/21/16
FBCO
09/21/16
UPGRADE
Target $41
FBCO
Outperform
Clovis upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Kennen MacKay upgraded Clovis Oncology (CLVS) to Outperform and raised his price target for the shares to $41 from $19. Clovis closed yesterday up 13%, or $3.92, to $34.83. The potential for a takeover "outweighs concerns surrounding patent life, limited experience in platinum resistant/refractory patients, and PARPi competition," MacKay tells investors in a research note. Clovis could be worth $35-$41 per share in a buyout on operational synergies, and $52-$55 per share with leveraged tax benefits, MacKay estimates. He points out that Eli Lilly (Lill)y, Merck (MRK), Japan's Takeda and others have expressed interest in acquiring U.S. oncology companies.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
10/07/16
LEER
10/07/16
NO CHANGE
LEER
Outperform
Incyte Epacadostat Phase 1 Melanoma data maturing well, says Leerink
Leerink analyst Michael Schmidt says the data from ECHO-202 Phase 1 study evaluating the combination of Incyte's (INCY) IDO1 inhibitor epacadostat with Merck's (MRK) Keytruda confirms the previously published results and appears to be maturing well. The analyst reiterates an Outperform rating on Incyte's shares, saying Jakafi remains a compelling long-term growth driver for the company, expectations for baricitinib are still moderate, and its maturing oncology pipeline of 14 molecules including epacadostat represents a long-term value driver.

TODAY'S FREE FLY STORIES

VRSN

VeriSign

$93.77

0.97 (1.05%)

18:36
06/28/17
06/28
18:36
06/28/17
18:36
Hot Stocks
VeriSign says renews .net control through 2023 »

VeriSign disclosed in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DD

DuPont

$81.28

0.59 (0.73%)

, DOW

Dow Chemical

$63.25

0.62 (0.99%)

18:34
06/28/17
06/28
18:34
06/28/17
18:34
Hot Stocks
DuPont, Dow Chemical boards reiterate support of merger agreement »

Dow Chemical Company…

DD

DuPont

$81.28

0.59 (0.73%)

DOW

Dow Chemical

$63.25

0.62 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

TPX

Tempur Sealy

$50.87

0.07 (0.14%)

18:33
06/28/17
06/28
18:33
06/28/17
18:33
Hot Stocks
Tempur Sealy enters standstill pact with H Partners, board member Nabi »

Tempur Sealy disclosed in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALJ

Alon USA Energy

$13.33

0.15 (1.14%)

, DK

Delek US

$26.43

0.25 (0.95%)

18:26
06/28/17
06/28
18:26
06/28/17
18:26
Hot Stocks
Alon USA Energy stockholders approve Delek US merger »

Alon USA Energy (ALJ)…

ALJ

Alon USA Energy

$13.33

0.15 (1.14%)

DK

Delek US

$26.43

0.25 (0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

ANCUF

Alimentation Couche-Tard

$49.30

0.144 (0.29%)

, CST

CST Brands

18:25
06/28/17
06/28
18:25
06/28/17
18:25
Hot Stocks
Alimentation Couche-Tard confirms closing of CST Brands acquisition »

Alimentation Couche-Tard…

ANCUF

Alimentation Couche-Tard

$49.30

0.144 (0.29%)

CST

CST Brands

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BK

BNY Mellon

$50.60

0.92 (1.85%)

18:04
06/28/17
06/28
18:04
06/28/17
18:04
Hot Stocks
BNY Mellon announces strategic alliance with One Investment Group »

BNY Mellon and One…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

PRGS

Progress Software

$30.82

0.74 (2.46%)

, WOR

Worthington

$47.36

2 (4.41%)

18:03
06/28/17
06/28
18:03
06/28/17
18:03
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

PRGS

Progress Software

$30.82

0.74 (2.46%)

WOR

Worthington

$47.36

2 (4.41%)

GEMP

Gemphire Therapeutics

$12.27

0.43 (3.63%)

NXTD

Nxt-ID

$1.66

0.2505 (17.77%)

KLIC

Kulicke & Soffa

$20.02

0.53 (2.72%)

SRPT

Sarepta

$33.86

0.83 (2.51%)

SPLS

Staples

$9.93

0.77 (8.41%)

FITB

Fifth Third

$25.49

0.4 (1.59%)

DFS

Discover

$61.88

0.81 (1.33%)

STI

SunTrust

$56.09

0.88 (1.59%)

C

Citi

$65.18

0.95 (1.48%)

RF

Regions Financial

$14.09

0.09 (0.64%)

BK

BNY Mellon

$50.60

0.92 (1.85%)

JPM

JPMorgan

$89.82

1.77 (2.01%)

CFG

Citizens Financial

$35.34

0.5 (1.44%)

BAC

Bank of America

$23.88

0.61 (2.62%)

MS

Morgan Stanley

$44.32

0.1 (0.23%)

WFC

Wells Fargo

$54.33

1.17 (2.20%)

PNC

PNC Financial

$123.40

2.28 (1.88%)

ZION

Zions Bancorp

$42.97

0.43 (1.01%)

GS

Goldman Sachs

$223.22

2.94 (1.33%)

AXP

American Express

$83.97

0.89 (1.07%)

USB

U.S. Bancorp

$51.98

0.84 (1.64%)

PIR

Pier 1 Imports

$5.38

0.04 (0.75%)

BLCM

Bellicum Pharmaceuticals

$13.32

0.18 (1.37%)

AKBA

Akebia

$15.50

-0.19 (-1.21%)

DOC

Physicians Realty Trust

$21.60

0.08 (0.37%)

CRZO

Carrizo Oil & Gas

$15.61

-0.47 (-2.92%)

COF

Capital One

$82.98

1.6 (1.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 28

    Jun

  • 28

    Jun

  • 29

    Jun

  • 14

    Jul

  • 14

    Jul

  • 14

    Jul

  • 14

    Jul

  • 18

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 20

    Jul

  • 20

    Jul

  • 20

    Jul

  • 21

    Jul

  • 21

    Jul

  • 21

    Jul

  • 21

    Jul

  • 25

    Jul

  • 26

    Jul

  • 03

    Aug

  • 26

    Sep

  • 12

    Oct

  • 12

    Oct

  • 17

    Oct

  • 18

    Oct

  • 30

    Oct

  • 15

    Jan

  • 17

    Jan

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

  • 29

    Jun

  • 29

    Jun

  • 29

    Jun

VRX

Valeant

$17.15

0.5 (3.00%)

18:02
06/28/17
06/28
18:02
06/28/17
18:02
Hot Stocks
Salix confirms FDA accepts NDA for PLENVU »

Valeant…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

NTNX

Nutanix

$20.36

1.72 (9.23%)

, GOOG

Alphabet

$940.49

13.16 (1.42%)

18:02
06/28/17
06/28
18:02
06/28/17
18:02
Hot Stocks
Nutanix announces strategic alliance with Google Cloud »

Nutanix (NTNX) announced…

NTNX

Nutanix

$20.36

1.72 (9.23%)

GOOG

Alphabet

$940.49

13.16 (1.42%)

GOOGL

Alphabet Class A

$961.01

12.92 (1.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

CE

Celanese

$93.42

0.62 (0.67%)

18:02
06/28/17
06/28
18:02
06/28/17
18:02
Hot Stocks
Celanese increases price of Dibutyl Maleate and Dioctyl Maleate in Europe »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$223.22

2.94 (1.33%)

18:00
06/28/17
06/28
18:00
06/28/17
18:00
Hot Stocks
Goldman Sachs: Fed did not object to capital plan »

Goldman Sachs announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 17

    Oct

COLB

Columbia Banking

$39.35

0.49 (1.26%)

17:56
06/28/17
06/28
17:56
06/28/17
17:56
Hot Stocks
Columbia Banking names Hadley Robbins CEO »

Columbia Banking System…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFBK

Northfield Bancorp

$17.36

0.3 (1.76%)

17:55
06/28/17
06/28
17:55
06/28/17
17:55
Hot Stocks
Northfield Bancorp CEO John Alexander to retire, Steven Klein to succeed »

Northfield Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JBLU

JetBlue

$22.96

0.25 (1.10%)

, AAL

American Airlines

$49.25

0.75 (1.55%)

17:43
06/28/17
06/28
17:43
06/28/17
17:43
Hot Stocks
Homeland Security announces new aviation security measures »

Secretary of Homeland…

JBLU

JetBlue

$22.96

0.25 (1.10%)

AAL

American Airlines

$49.25

0.75 (1.55%)

UAL

United Continental

$76.70

0.7 (0.92%)

DAL

Delta Air Lines

$53.84

1 (1.89%)

LUV

Southwest

$62.01

0.5 (0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jun

  • 07

    Jul

TD

Toronto-Dominion

$50.43

0.86 (1.73%)

17:38
06/28/17
06/28
17:38
06/28/17
17:38
Hot Stocks
Toronto-Dominion confirms Fed did not object to 2017 capital plan »

"The Board of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SC

Santander Consumer

$12.52

0.13 (1.05%)

, SAN

Banco Santander

$6.85

0.19 (2.85%)

17:32
06/28/17
06/28
17:32
06/28/17
17:32
Hot Stocks
Santander Consumer confirms portion of Santander USA capital plan »

Santander Consumer (SC)…

SC

Santander Consumer

$12.52

0.13 (1.05%)

SAN

Banco Santander

$6.85

0.19 (2.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSGP

CoStar Group

$265.43

2.65 (1.01%)

17:30
06/28/17
06/28
17:30
06/28/17
17:30
Hot Stocks
CoStar Group sued by Xceligent for antitrust violations »

Xceligent, a provider of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

BGCP

BGC Partners

$12.16

0.06 (0.50%)

17:29
06/28/17
06/28
17:29
06/28/17
17:29
Earnings
BGC Partners sees Q2 revenues near high end of previous range, consensus $702M »

Prior view was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WOR

Worthington

$47.36

2 (4.41%)

17:27
06/28/17
06/28
17:27
06/28/17
17:27
Earnings
Worthington reports Q4 EPS 87c, consensus 83c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 30

    Oct

HBAN

Huntington Bancshares

$13.14

0.23 (1.78%)

17:25
06/28/17
06/28
17:25
06/28/17
17:25
Hot Stocks
Huntington Bancshares plans to raise dividend 38%, repurchase $308M of stock »

Huntington Bancshares was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jul

SPLS

Staples

$9.94

0.78 (8.52%)

17:20
06/28/17
06/28
17:20
06/28/17
17:20
Hot Stocks
Staples to be acquired by Sycamore Partners for roughly $6.9B »

Staples and Sycamore…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPLS

Staples

$9.93

0.77 (8.41%)

17:19
06/28/17
06/28
17:19
06/28/17
17:19
Hot Stocks
Breaking Hot Stocks news story on Staples »

Staples to be acquired by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPLS

Staples

$9.93

0.77 (8.41%)

17:19
06/28/17
06/28
17:19
06/28/17
17:19
Hot Stocks
Breaking Hot Stocks news story on Staples »

Staples trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSG

Overseas Shipholding

$2.84

0.29 (11.37%)

17:18
06/28/17
06/28
17:18
06/28/17
17:18
Hot Stocks
Overseas Shipholding CFO Christopher Wolf resigns »

Overseas Shipholding…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$280.02

2.19 (0.79%)

17:18
06/28/17
06/28
17:18
06/28/17
17:18
Hot Stocks
Lockheed Martin awarded $257.8M government contract modification »

Lockheed Martin Corp.,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.